164.11
前日終値:
$162.22
開ける:
$163.44
24時間の取引高:
460.86K
Relative Volume:
0.48
時価総額:
$8.60B
収益:
$708.24M
当期純損益:
$-188.30M
株価収益率:
-43.89
EPS:
-3.7392
ネットキャッシュフロー:
$-70.99M
1週間 パフォーマンス:
-3.51%
1か月 パフォーマンス:
-19.58%
6か月 パフォーマンス:
-10.90%
1年 パフォーマンス:
+26.65%
Axsome Therapeutics Inc Stock (AXSM) Company Profile
名前
Axsome Therapeutics Inc
セクター
電話
(212) 332-3241
住所
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc
|
164.11 | 8.60B | 708.24M | -188.30M | -70.99M | -3.7392 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
237.88 | 94.97B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.50 | 82.52B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
849.70 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-23 | 再開されました | Truist | Buy |
| 2026-07-21 | 開始されました | BMO Capital Markets | Outperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 開始されました | B. Riley Securities | Buy |
| 2025-09-03 | 再開されました | Wells Fargo | Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | 開始されました | Oppenheimer | Outperform |
| 2025-04-07 | 開始されました | Jefferies | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-12-31 | 繰り返されました | Mizuho | Outperform |
| 2024-09-03 | 開始されました | Wells Fargo | Overweight |
| 2024-08-06 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-04-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2024-01-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-08-08 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 開始されました | Piper Sandler | Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2022-09-07 | 再開されました | Mizuho | Buy |
| 2021-08-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 開始されました | Berenberg | Buy |
| 2021-01-08 | 開始されました | Jefferies | Buy |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-09-29 | 開始されました | BofA Securities | Underperform |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-14 | 開始されました | Cowen | Outperform |
| 2019-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-16 | 繰り返されました | Guggenheim | Buy |
| 2019-10-16 | 開始されました | Guggenheim | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-28 | 開始されました | SunTrust | Buy |
| 2019-05-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-08 | 開始されました | SVB Leerink | Outperform |
| 2019-03-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2015-12-15 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Axsome Therapeutics Inc (AXSM) 最新ニュース
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Why Axsome Therapeutics shares are falling today - Quiver Quantitative
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X - TradingView
Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% - Trefis
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - Yahoo Finance
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Motley Fool
Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities - The Globe and Mail
Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss - Trefis
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis
Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk - Moomoo
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada - MarketBeat
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 - GlobeNewswire
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting - Lelezard
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - tradingview.com
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - tradingview.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics Announces Results of the Shared Goals - globenewswire.com
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Axsome Therapeutics Inc (AXSM) 財務データ
収益
当期純利益
現金流量
EPS
Axsome Therapeutics Inc (AXSM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
| Mark Jacobson | Officer |
Sep 03 '26 |
Proposed Sale |
208.35 |
10,000 |
2,083,500 |
0 |
| Herriot Tabuteau | Officer |
Aug 06 '26 |
Proposed Sale |
210.13 |
4,660 |
979,206 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Sale |
213.95 |
4,660 |
997,007 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
4.95 |
4,660 |
23,067 |
11,889 |
| Herriot Tabuteau | Officer |
Aug 05 '26 |
Proposed Sale |
212.85 |
45,004 |
9,579,101 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Option Exercise |
4.95 |
45,004 |
222,770 |
52,233 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Sale |
212.01 |
45,004 |
9,541,298 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Sale |
240.25 |
49,666 |
11,932,256 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
4.95 |
49,666 |
245,847 |
56,895 |
大文字化:
|
ボリューム (24 時間):